Objective. Tuberculosis and HIV coinfection poses unique clinical and psychosocial complexities that can impact nonadherence to highly active antiretroviral treatment (HAART). Methods. This was a prospective case series to identify risk factors for HAART nonadherence among 43 patients with HIV and tuberculosis (TB) in Lima, Peru. Nonadherence was defined by patient self-report. Results. The median initial CD4 and HIV viral load were 63 and 159,000, respectively. Patients had received a median of 6.1 months of ART. Univariable analysis found low social support, substance use, and depression to be associated with nonadherence. In multivariable analysis, low social support was associated with nonadherence. Conclusions. In the authors' urban cohort of HIV-TB coinfected individuals in Lima, Peru, substance use, depression, and lack of social support were key barriers to adherence. These findings suggest that adherence interventions may be unsuccessful unless they target the underlying psychosocial challenges faced by patients living with TB and AIDS.
Merten S., Haller T.Culture, changing livelihoods, and HIV/AIDS discourse: reframing the institutionalization of fish-for-sex exchange in the Zambian Kafue Flats. Cult Health Sex. 2007;9:69-83.
2.
Smith Fawzi MC , Lambert W., Singler JM, et al. Factors associated with forced sex among women accessing health services in rural Haiti: implications for the prevention of HIV infection and other sexually transmitted diseases. Soc Sci Med. 2005;60:679-689.
3.
Low N., Egger M., Gorter A., et al. AIDS in Nicaragua: epidemiological, political, and sociocultural perspectives. Int J Health Serv. 1993;23:685-702.
4.
Malow RM, Cassagnol T., McMahon R., Jennings TE, Roatta VGRelationship of psychosocial factors to HIV risk among Haitian women. AIDS Educ Prev. 2000;12:79-92.
5.
Karamagi CA, Tumwine JK, Tylleskar T., Heggenhougen K.Intimate partner violence against women in eastern Uganda: implications for HIV prevention. BMC Public Health. 2006;6:284.
6.
Ponticiello A., Sturkenboom MC, Simonetti A., Ortolani R., Malerba M., Sanduzzi A.Deprivation, immigration and tuberculosis incidence in Naples, 1996-2000. Eur J Epidemiol. 2005;20:729-734.
7.
Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Mendez A.Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984-1992. Am J Public Health. 2001;91:1487-1493.
8.
Killewo J.Poverty, TB, and HIV infection: a vicious cycle. J Health Popul Nutr. 2002;20:281-284.
9.
Souza WV, Ximenes R., Albuquerque MF, et al. The use of socio-economic factors in mapping tuberculosis risk areas in a city of northeastern Brazil. Rev Panam Salud Publica . 2000;8:403-410.
10.
Mukherjee JS , Ivers L., Leandre F., Farmer P., Behforouz H.Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr.2006;43(Suppl 1):S123-S126.
11.
Castro R., Orozco E., Eroza E., Manca MC, Hernandez JJ, Aggleton P.AIDS-related illness trajectories in Mexico: findings from a qualitative study in two marginalized communities. AIDS Care. 1998;10:583-598.
12.
Leserman J. , Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397-406.
13.
Lyketsos CG , Hoover DR, Guccione M., et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry . 1996;153:1430-1437.
14.
Meng X., Anderson AF, Hou X., et al. A pilot project for the effective delivery of HAART in rural China. AIDS Patient Care STDS. 2006;20:213-219.
15.
Laniece I., Ciss M., Desclaux A., et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adultsAIDS.2003;17(Suppl 3):S103-S108.
16.
Orrell C.Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep. 2005;2:171-176.
17.
Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
18.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SAPredictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
19.
Eldred LJ, Wu AW, Chaisson RE, Moore RDAdherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-125.
20.
Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TLPatterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
21.
Tuldra A., Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221-228.
22.
Nemes MI, Carvalho HB, Souza MFAntiretroviral therapy adherence in BrazilAIDS.2004;18(Suppl 3):S15-S20.
23.
Pinheiro CA , de-Carvalho-Leite JC, Drachler ML, Silveira VLFactors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. Braz J Med Biol Res. 2002;35:1173-1181.
24.
Bastardo YM , Kimberlin CLRelationship between quality of life, social support and disease-related factors in HIV-infected persons in Venezuela. AIDS Care. 2000;12:673-684.
25.
Rowe KA, Makhubele B., Hargreaves JR, Porter JD, Hausler HP, Pronyk PMAdherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings ? Int J Tuberc Lung Dis. 2005;9:263-269.
26.
World Health Organization.The Five Elements of DOTS Available at: http://www.who.int/tb/dots/whatisdots/en/index.html . Accessed April 15, 2007.
27.
Chimzizi R. , Harries AD, Gausi F., et al. Scaling up HIV/AIDS and joint HIV-TB services in Malawi. Int J Tuberc Lung Dis. 2005;9:582-584.
28.
Libamba E., Makombe S., Harries AD, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes-the case of Malawi. Int J Tuberc Lung Dis . 2005;9:1062-1071.
29.
Wang Y., Collins C., Vergis M., Gerein N., Macq J.HIV/AIDS and TB: contextual issues and policy choice in programme relationships . Trop Med Int Health. 2007;12:183-194.
30.
Cohen J.HIV/AIDS: Latin America & Caribbean. South America. Science . 2006;313:484.
31.
Peruvian Ministry of Health.Analysis of the Epidemiologic Situation of HIV/AIDS in Peru. Available at: http://www.oge.sld.pe/publicaciones/pub_asis/asis19.pdf . Accessed April 15, 2007.
32.
Zavaleta C. , Fernandez C., Konda K., Valderrama Y., Vermund SH, Gotuzzo E.High prevalence of HIV and syphilis in a remote native community of the Peruvian Amazon. Am J Trop Med Hyg . 2007;76:703-705.
33.
Sebastian JL , Munoz M., Palacios E., et al. Scaling up HIV treatment in Peru: applying lessons from DOTS-Plus. J Int Assoc Physicians AIDS Care (Chic Ill). 2006;5:137-142.
34.
World Health Organization.Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health ApproachGeneva, Switzerland: World Health Organization.
35.
Derogatis LR , Lipman RS, Rickels K., Uhlenhuth EH, Covi L.The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry . 1974,7:79-110.
36.
Derogatis LR , Lipman RS, Rickels K., Uhlenhuth EH, Covi L.The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19:1-15.
37.
Joseph JG, Caumartin SM, Tal M., et al. Psychological functioning in a cohort of gay men at risk for AIDS. A three-year descriptive study. J Nerv Ment Dis. 1990;178:607-615.
38.
Kaaya SF, Fawzi MC, Mbwambo JK, Lee B., Msamanga GI, Fawzi W.Validity of the Hopkins Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania. Acta Psychiatr Scand. 2002 ;106:9-19.
39.
Lackner JB, Joseph JG, Ostrow DG, Eshleman S.The effects of social support on Hopkins Symptom Checklist-assessed depression and distress in a cohort of human immunodeficiency virus-positive and -negative gay men. A longitudinal study at six time points. J Nerv Ment Dis. 1993;181:632-638.
40.
Weiss JJ, Mulder CL, Antoni MH, de Vroome EM, Garssen B., Goodkin K.Effects of a supportive-expressive group intervention on long-term psychosocial adjustment in HIV-infected gay men. Psychother Psychosom. 2003;72:132-140.
41.
Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BHThe Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care. 1988;26:709-723.
42.
Remor E.Social support and quality of life in the HIV infection [in Spanish]. Aten Primaria. 2002;30:143-148.
43.
Bellon Saameno JA, Delgado Sanchez A., Luna del Castillo JD, Lardelli Claret P.Validity and reliability of the Duke-UNC-11 questionnaire of functional social support [in Spanish]. Aten Primaria. 1996;18:153-156, 158-163.
44.
Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
45.
Clayson DJ, Wild DJ, Quarterman P., Duprat-Lomon I., Kubin M., Coons SJA comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006;24:751-765.
46.
Badia X., Podzamczer D., Casado A., Lopez-Lavid C., Garcia M.Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires . Spanish MOS-HIV and MQOL-HIV Validation Group. AIDS. 2000;14:1439-1447.
47.
Berger BE, Ferrans CE, Lashley FRMeasuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24:518-529.
48.
Behforouz HL , Kalmus A., Scherz CS, Kahn JS, Kadakia MB, Farmer PEDirectly observed therapy for HIV antiretroviral therapy in an urban US setting. J Acquir Immune Defic Syndr . 2004;36:642-645.
49.
Andersen R. , Bozzette S., Shapiro M., et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res . 2000;35:389-416.
50.
Shively M., Smith T., Bormann J., Gifford A.Evaluating self-efficacy for HIV disease management skills. AIDS Behav. 2002;6:371-379.
51.
Van Der Ven NC, Weinger K., Yi J., et al. The confidence in diabetes self-care scale: psychometric properties of a new measure of diabetes-specific self-efficacy in Dutch and US patients with type 1 diabetes. Diabetes Care . 2003;26:713-718.
52.
Smith SR, Rublein JC, Marcus C., Brock TP, Chesney MAA medication self-management program to improve adherence to HIV therapy regimens . Patient Educ Couns. 2003;50:187-199.
53.
Oyugi JH, Byakika-Tusiime J., Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting . J Acquir Immune Defic Syndr. 2004;36:1100-1102.
54.
Hinton WL, Du N., Chen YC, Tran CG, Newman TB, Lu FGScreening for major depression in Vietnamese refugees: a validation and comparison of two instruments in a health screening population. J Gen Intern Med. 1994;9:202-206.
55.
Mollica RF, Wyshak G., de Marneffe D., Khuon F., Lavelle J.Indochinese versions of the Hopkins Symptom Checklist-25: a screening instrument for the psychiatric care of refugees. Am J Psychiatry. 1987;144:497-500.
56.
Cargill VA, Stone VEHIV/AIDS: a minority health issue. Med Clin North Am. 2005;89:895-912.
57.
Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115-123.
58.
van Oosterhout JJ, Bodasing N., Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-470.
59.
Brouwer CN, Lok CL, Wolffers I., Sebagalls S.Psychosocial and economic aspects of HIV/AIDS and counselling of care-takers of HIV-infected children in Uganda. AIDS Care. 2000;12:535-540.
60.
Nachega JB, Knowlton AR, Deluca A., et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adultsA qualitative study. J Acquir Immune Defic Syndr.2006;43(Suppl 1):S127-S133.
61.
van Servellen G., Chang B., Garcia L., Lombardi E.Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS. 2002;16:269-281.
62.
Conover CJ, Arno P., Weaver M., Ang A., Ettner SLIncome and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders. J Ment Health Policy Econ. 2006;9:71-86.
63.
van Servellen G., Lombardi E.Supportive relationships and medication adherence in HIV-infected, low-income Latinos. West J Nurs Res. 2005;27:1023-1039.
64.
Viswanathan H., Anderson R., Thomas J. 3rd.Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center. Qual Life Res. 2005;14:935-944.
65.
Sebastián J., Muñoz L., Mestanza L., et al. Atencion Integral en la comunidad a personas pobres con VIH/SIDA- TB en LIMA ESTE-Peru IVFORO Comunitario 2007 Latinoamericano y del Caribe en VIH/SIDA e ITS. Argentina; April 16-20, 2007 .
66.
Weidle PJ, Wamai N., Solberg P., et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368:1587-1594.
67.
Malta M., Carneiro-da-Cunha C., Kerrigan D., Strathdee SA, Monteiro M., Bastos FICase management of human immunodeficiency virus-infected injection drug users: a case study in Rio de Janeiro, BrazilClin Infect Dis.2003;37(Suppl 5):S386-S391.
68.
Demeester R. , Omes C., Karasi JC, et al. Adherence to first-line antiretroviral regimens in Rwanda. J Acquir Immune Defic Syndr. 2005;40:113-114.
69.
Farmer P., Leandre F., Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001;358:404-409.
Badia X., Podzamczer D., Garcia M., Lopez-Lavid CC, Consiglio E.A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey. AIDS. 1999;13:1727-1735.
72.
Lau JT, Tsui HY, Patrick LC, Rita CW, Molassiotis A.Validation of a Chinese version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) among Chinese people living with HIV/AIDS in Hong Kong. Qual Life Res. 2006;15:1079-1089.
73.
McDonnell KA , Gielen AC, O'Campo P., Burke JGAbuse, HIV status and health-related quality of life among a sample of HIV positive and HIV negative low income women. Qual Life Res. 2005;14:945-957.
74.
Ichikawa M. , Natpratan C.Quality of life among people living with HIV/AIDS in northern Thailand: MOS-HIV Health Survey. Qual Life Res . 2004;13:601-610.
75.
Paton NI, Chapman CA, Chan SP, et al. Validation of the Medical Outcomes Study HIV Health Survey as a measure of quality of life in HIV-infected patients in Singapore. Int J STD AIDS. 2002;13:456-461.
